Last Updated : May 19, 2017
Details
FilesGeneric Name:
Alectinib
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Alecensaro
Project Line:
Reimbursement Review
Project Number:
PC0092-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
150 mg capsule
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (with CNS metastases)
Funding Request:
As monotherapy for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib and have CNS metastases
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : May 19, 2017